The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy

ConclusionThe present results suggest that the achieved EPA/AA ratio, but not the absolute change in EPA/AA ratio, following EPA therapy might be a useful marker for the risk stratification of CAD among statin-treated patients with a high non-HDL-C level.Clinical Trial RegistrationUMIN (http://www.umin.ac.jp/) Study ID: UMIN000010452.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research